image
Basic Materials - Construction Materials - NASDAQ - US
$ 29.44
-0.574 %
$ 156 M
Market Cap
24.13
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SMID stock under the worst case scenario is HIDDEN Compared to the current market price of 29.4 USD, Smith-Midland Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SMID stock under the base case scenario is HIDDEN Compared to the current market price of 29.4 USD, Smith-Midland Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SMID stock under the best case scenario is HIDDEN Compared to the current market price of 29.4 USD, Smith-Midland Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SMID

image
$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
59.6 M REVENUE
18.85%
1.12 M OPERATING INCOME
30.91%
795 K NET INCOME
-0.62%
7.73 M OPERATING CASH FLOW
222.07%
-4.66 M INVESTING CASH FLOW
-77.27%
-619 K FINANCING CASH FLOW
-28.15%
23.6 M REVENUE
20.08%
3.85 M OPERATING INCOME
43.96%
3.15 M NET INCOME
59.01%
3.87 M OPERATING CASH FLOW
43.07%
-2.02 M INVESTING CASH FLOW
2.13%
-131 K FINANCING CASH FLOW
17.61%
Balance Sheet Smith-Midland Corporation
image
Current Assets 33.3 M
Cash & Short-Term Investments 9.18 M
Receivables 17.7 M
Other Current Assets 6.42 M
Non-Current Assets 28 M
Long-Term Investments 0
PP&E 27.7 M
Other Non-Current Assets 343 K
14.96 %28.91 %10.46 %45.12 %Total Assets$61.3m
Current Liabilities 16 M
Accounts Payable 7.34 M
Short-Term Debt 679 K
Other Current Liabilities 8 M
Non-Current Liabilities 11.2 M
Long-Term Debt 5.09 M
Other Non-Current Liabilities 6.08 M
26.98 %29.44 %18.74 %22.35 %Total Liabilities$27.2m
EFFICIENCY
Earnings Waterfall Smith-Midland Corporation
image
Revenue 59.6 M
Cost Of Revenue 48.9 M
Gross Profit 10.7 M
Operating Expenses 9.53 M
Operating Income 1.12 M
Other Expenses 323 K
Net Income 795 K
60m60m50m50m40m40m30m30m20m20m10m10m0060m(49m)11m(10m)1m(323k)795kRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
17.88% GROSS MARGIN
17.88%
1.88% OPERATING MARGIN
1.88%
1.33% NET MARGIN
1.33%
2.33% ROE
2.33%
1.30% ROA
1.30%
1.46% ROIC
1.46%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Smith-Midland Corporation
image
6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)20152015201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 795 K
Depreciation & Amortization 2.4 M
Capital Expenditures -5.01 M
Stock-Based Compensation 375 K
Change in Working Capital 4.96 M
Others 4.5 M
Free Cash Flow 2.72 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Smith-Midland Corporation
image
SMID has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.055 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.0600.0600.0500.0500.0400.0400.0300.0300.0200.0200.0100.0100.0000.0000.040.040.010.010.050.050.0550.060.0550.062015201520162016201720172018201820192019
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Smith-Midland Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
48.7 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Hotchkis & Wiley Launches SMID-Cap Diversified Value ETF (HWSM) LOS ANGELES--(BUSINESS WIRE)--Global investment manager Hotchkis & Wiley launches first ETF, the Hotchkis & Wiley SMID-Cap Diversified Value Fund (HWSM). businesswire.com - 3 weeks ago
Smith-Midland Awarded $5M SlenderWall Contract for FBI Project Smith-Midland to Produce SlenderWall for FBI Dorm Re-Cladding Project in Virginia MIDLAND, VA / ACCESS Newswire / April 3, 2025 / Smith-Midland Corporation (NASDAQ:SMID), a provider of innovative, high-quality proprietary and patented precast concrete products and systems, has been selected to produce more than $5M of SlenderWall and architectural precast concrete panels for existing dormitories at the Federal Bureau of Investigation (FBI) in Quantico, Virginia. Production of SlenderWall, Smith-Midland's high-performance, lightweight precast concrete cladding system, is set to begin in June 2025 at the company's Virginia plant, with installation slated for October 2025. accessnewswire.com - 4 weeks ago
Smith-Midland Announces Delayed Filing of 2024 Form 10-K and Announces Preliminary Full-Year Revenue MIDLAND, VA / ACCESS Newswire / March 31, 2025 / Smith-Midland Corporation (NASDAQ:SMID) (the "Company"), a provider of innovative, high-quality proprietary and patented precast concrete products and systems, today announced that it has filed a Form 12b-25 with the Securities and Exchange Commission to provide notice of the late filing of its Annual Report on Form 10-K ("Form 10-K") for the year ended December 31, 2024. The company expects to file its Form 10-K on or before April 15, 2025. accessnewswire.com - 1 month ago
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT. globenewswire.com - 2 months ago
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference, which is taking place from February 5-6, 2025, in New York, NY. globenewswire.com - 3 months ago
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference. globenewswire.com - 3 months ago
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found. businesswire.com - 3 months ago
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. newsfilecorp.com - 3 months ago
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 10:00 a.m. Eastern time. globenewswire.com - 3 months ago
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET. A live webcast of this event will be available on the Investors & Media section of Mersana's website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event. globenewswire.com - 3 months ago
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET. globenewswire.com - 3 months ago
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET. globenewswire.com - 3 months ago
8. Profile Summary

Smith-Midland Corporation SMID

image
COUNTRY US
INDUSTRY Construction Materials
MARKET CAP $ 156 M
Dividend Yield 0.00%
Description Smith-Midland Corporation, through its subsidiaries, invents, develops, manufactures, markets, leases, licenses, sells, and installs precast concrete products primarily for use in the construction, highway, utilities, and farming industries. It offers SlenderWall, a patented, lightweight, energy efficient concrete and steel exterior wall panel for use in building construction; Sierra Wall that provides sound and sight barrier for use alongside highways around residential, industrial, and commercial properties; J-J Hooks highway safety barriers for use on roadways to separate lanes of traffic in construction work zone or traffic control purposes; and Easi-Set precast building and Easi-Span expandable precast buildings for use in housing communications operations, traffic control systems, and mechanical and electrical stations. The company also provides Easi-Set utility vaults for house equipment, such as cable, telephone, or traffic signal equipment, and for underground storage, as well as custom-built utility vaults for special needs; SoftSound soundwall panels to absorb highway noise; Beach Prisms, an erosion control module for seawalls and jetties; and H2Out secondary drainage systems for panelized exterior cladding. In addition, it licenses its proprietary products in Canada, Australia, Belgium, Mexico, New Zealand, and Trinidad. The company markets its products through in-house sales force and independent sales representatives to contractors performing public and private construction contracts, such as construction of commercial buildings, public and private roads and highways, airports, and municipal utilities; and federal, state, and local transportation authorities. Smith-Midland Corporation was incorporated in 1960 and is based in Midland, Virginia.
Contact 5119 Catlett Road, Midland, VA, 22728 https://smithmidland.com
IPO Date Dec. 13, 1995
Employees 172
Officers Mr. Edward G. Broenniman Advisor Mr. Matthew I. Smith Vice President of Sales & Marketing, President of Concrete Safety Systems and Director Mr. Ashley B. Smith Chairman of the Board of Directors, President & Chief Executive Officer